Clinical trial
A 60-DAY, Open-label, Randomized Study to Evaluate the Efficacy and Safety of Eligen® B12 OR Intramuscularly Administered B12 in Subjects With Low Serum Cobalamin With a 30 Day Extension to 90 Days of Dosing
NCT01312831 is registered in ClinicalTrials.gov with Emisphere Technologies, Inc. as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- A 60-DAY, Open-label, Randomized Study to Evaluate the Efficacy and Safety of Eligen® B12 OR Intramuscularly Administered B12 in Subjects With Low Serum Cobalamin With a 30 Day Extension to 90 Days of Dosing
- Lead sponsor
- Emisphere Technologies, Inc.
- Phase
- Not applicable
- Overall status
- Completed
- Start date
- February 28, 2009
- Completion date
- December 31, 2010
- Enrollment
- 49 (actual)
- Sites
- Not reported
Conditions
As the registry lists them; a condition with its own page is linked.